Evidence map›Paper›PMID 28645652›Full record

ArticleBiochimica et biophysica acta. Molecular basis of disease2017

Androgen inhibits key atherosclerotic processes by directly activating ADTRP transcription.

Chunyan Luo, Elisabeth Pook, Bo Tang, Weiyi Zhang, Sisi Li, Kirsten Leineweber, Shing-Hu Cheung, Qiuyun Chen, Martin Bechem, Jing-Shan Hu and 2 more

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta. Molecular basis of disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Relationship between theAnimal biotechnology · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Long noncoding RNAThe Journal of biological chemistry · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Chunyan LuoKey Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Cardio-Institute, Huazhong University of Science and Technology, Wuhan 430074, PR China.
Elisabeth PookBayer AG, Drug Discovery, 42096 Wuppertal, Germany.
Bo TangKey Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Cardio-Institute, Huazhong University of Science and Technology, Wuhan 430074, PR China.
Weiyi ZhangBayer Healthcare Co Ltd, Innovation Center China, Beijing, PR China.
Sisi LiKey Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Cardio-Institute, Huazhong University of Science and Technology, Wuhan 430074, PR China.
Kirsten LeineweberBayer AG, Drug Discovery, 42096 Wuppertal, Germany.
Shing-Hu CheungBayer Healthcare Co Ltd, Innovation Center China, Beijing, PR China.
Qiuyun ChenCenter for Cardiovascular Genetics, Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH 44195, USA.
Martin BechemBayer AG, Drug Discovery, 42096 Wuppertal, Germany.
Jing-Shan HuBayer Healthcare Co Ltd, Innovation Center China, Beijing, PR China.
Volker LauxBayer AG, Drug Discovery, 42096 Wuppertal, Germany. Electronic address: volker.laux@bayer.com.
Qing Kenneth WangKey Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Cardio-Institute, Huazhong University of Science and Technology, Wuhan 430074, PR China; Center for Cardiovascular Genetics, Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH 44195, USA. Electronic address: qkwang@hust.edu.cn.
Bayer (Germany) · DEBayer (China) · CNHuazhong University of Science and Technology · CNCleveland Clinic Lerner College of Medicine · US

Funding

NGS in Large CAD Families: In-Depth Identification of Rare Risk Genomic VariantsR01HL121358 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI WANG, QING KENNETH · 2014 to 2017
$2.8M
Targeting Nav1.5 trafficking as a therapy for lethal genetic cardiac arrhythmiasR01HL126729 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI WANG, QING KENNETH · 2015 to 2018
$1.6M
NHLBI NIH HHS R01 HL121358NHLBI NIH HHS R01 HL126729
6 · The paper itself

Abstract

Low androgen levels are associated with an increased risk of coronary artery disease (CAD), thrombosis and myocardial infarction (MI), suggesting that androgen has a protective role. However, little is known about the underlying molecular mechanism. Our genome-wide association study identified the ADTRP gene encoding the androgen-dependent TFPI regulating protein as a susceptibility gene for CAD and MI. The expression level of ADTRP was regulated by androgen, but the molecular mechanism is unknown. In this study, we identified the molecular mechanism by which androgen regulates ADTRP expression and tested the hypothesis that androgen plays a protective role in cardiovascular disease by activating ADTRP expression. Luciferase assays with an ADTRP promoter luciferase reporter revealed that androgen regulated ADTRP transcription in a dose- and time-dependent manner, and the effect was abolished by three different androgen inhibitors, including pyrvinium pamoate, bicalutamide, and cyproterone acetate. Chromatin-immunoprecipitation showed that the androgen receptor bound to a half androgen response element (ARE, TGTTCT) located at +324bp from the ADTRP transcription start site. The ARE is required for concentration-dependent transcriptional activation of ADTRP. HL-60 monocyte adhesion to EAhy926 endothelial cells (ECs) and transmigration across the EC layer, the two processes critical to development of CAD and MI, were inhibited by androgen, but the effect was rescued by ADTRP siRNA and exacerbated by overexpression of ADTRP and its downstream genes PIK3R3 and MIA3. These data suggest that one molecular mechanism by which androgen confers protection against CAD is stimulation of ADTRP expression.

Indexed as

Response ElementsAndrogensAtherosclerosisCoculture TechniquesCoronary Artery DiseaseEndothelial CellsGene Expression RegulationGenome-Wide Association StudyHeLa CellsHL-60 CellsHumansMembrane ProteinsMonocytesTranscription, GeneticTransendothelial and Transepithelial MigrationADTRP protein, humanAndrogensMembrane ProteinsADTRPAndrogenAndrogen receptor (AR)AtherosclerosisCoronary artery disease (CAD)Monocyte adhesion to endothelial cellsMonocyte transmigration across endothelial cellsMyocardial infarction (MI)Transendothelial migration of monocytes

Identifiers

PMID28645652
PMCPMC5859308
OpenAlexW2647848565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.